Action ZNTL ZENTALIS PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Zentalis Pharmaceuticals, Inc.

Actions

ZNTL

US98943L1070

Temps réel estimé Cboe BZX
Autres places de cotation
 20:02:20 06/05/2024 		Varia. 5j. Varia. 1 janv.
11,76 USD +0,47% Graphique intraday de Zentalis Pharmaceuticals, Inc. +2,80% -22,51%
11/04 Zentalis Pharmaceuticals, Inc. annonce des changements au sein de sa direction CI
02/04 Zentalis Pharmaceuticals présentera des données précliniques démontrant que l'inhibiteur de Wee1, l'azénosertib, exerce une activité anti-tumorale synergique avec les inhibiteurs de Kras(G12c) lors de la réunion annuelle de l'AACR 2024 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals, Inc. Announces Executive Changes
Zentalis Pharmaceuticals, Inc. Announces CFO Changes
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS Inhibitors at AACR Annual Meeting 2024
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating That Wee1 Inhibitor Azenosertib Exerts Synergistic Anti-Tumor Activity with Kras(G12c) Inhibitors At Aacr Annual Meeting 2024
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals Names Chief Medical Officer, Chief Business Officer
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
Zentalis Pharmaceuticals, Inc. Announces Executive Changes
Immunome, Inc. and Zentalis Pharmaceuticals, Inc. Enter into an Exclusive, Worldwide License Agreement Under Which Immunome Has Licensed from Zentalis ZPC-21, A Preclinical Ror1 Antibody-Drug Conjugate
Zentalis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ZNTL
  4. Actualités Zentalis Pharmaceuticals, Inc.
  5. Autres langues